



Monday, August 8<sup>th</sup>, 2016

**President**

DAYNNA WOLFF, Ph.D., FACMG  
Medical University of South Carolina  
Charleston, SC, USA

**President-Elect**

GORDANA RACA, MD, PhD, FACMG  
University of Southern California  
Children's Hospital Los Angeles  
Los Angeles, CA, USA

**Past-President**

STUART SCHWARTZ, PhD, FACMG  
Laboratory Corporation of America  
Research Triangle Park, NC, USA

**Secretary**

MIN FANG, MD, PhD, FACMG  
University of Washington Medical Center  
Fred Hutchinson Cancer Research Center  
Seattle, WA, USA

**Treasurer**

LINDA D. COOLEY, MD, MBA  
UMKC School of Medicine  
Children's Mercy Hospital  
Kansas City, MO, USA

**Board of Directors**

LYNNE V. ABRUZZO, MD, PhD, FACMG, FCAP  
The Ohio State University Wexner Medical Center  
Columbus, OH, USA

ADRIAN M. DUBUC, PhD, FACMG  
Harvard Medical School  
Brigham and Women's Hospital  
Boston, MA, USA

HUTTON M. KEARNEY, PhD, FACMG  
Mayo Clinic  
Rochester, MN, USA

ALAN LENNON, PhD, FACMG  
PathGroup  
Nashville, TN, USA

BRYNN LEVY, MSc(Med), PhD, FACMG  
Columbia University Medical Center  
New York Presbyterian Hospital  
New York, NY, USA

**Ad Hoc Member**

SCOTT NEWMAN, PhD  
St. Jude Children's Research Hospital  
Memphis, TN, USA

**Consulting Advisors**

MARILYN M. LI, MD, FACMG  
University of Pennsylvania Medical School,  
Children's Hospital of Philadelphia,  
Philadelphia, PA, USA

M. ANWAR IQBAL, PhD, FACMG  
University of Rochester Medical Center, NY  
Rochester, NY, USA

**Junior Board Member**

KAI LEE YAP, PhD  
University of Chicago,  
Chicago, IL, USA

Dear members and friends of the Cancer Genomics Consortium,

We are pleased to announce that the Cancer Genomics Consortium (CGC) has joined forces with the American College of Medical Genetics (ACMG) Laboratory Quality Assurance Committee to develop standards and guidelines for the interpretation and reporting of acquired copy number variants (CNVs) and copy neutral (CN)-loss of heterozygosity (LOH) in cancer.

This effort was developed to build upon current ACMG standard and guidelines for microarray analysis (Genet Med 2013;15:484-494) to achieve a more detailed, uniform system to assign clinical significance to acquired CNVs and CN-LOH. The new guidelines will develop a process for classifying acquired variants, based on objective criteria using an evidence-based weighing system.

The project has been approved by the ACMG and CGC Board of Directors, and will be carried out by a joint expert group over the next 12 to 18 months, with input from members of both organizations. The final approved version will be published in *Genetics in Medicine* and the ACMG and CGC websites. While the proposed standards and guidelines are mainly intended for interpreting and reporting variants detected by chromosomal microarray analysis, the newly developed interpretation algorithm will also be applicable to acquired structural variants detected by next-generation sequencing as the clinical testing moves more towards this technology.

We look forward to sharing this work with the community!

Regards,

A handwritten signature in black ink that reads 'Daynna'.

Daynna Wolff, Ph.D. FACMG  
CGC President

A handwritten signature in black ink that reads 'Gordana Raca'.

Gordana Raca, M.D., Ph.D. FACMG  
CGC President-Elect